EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation

Lan Ren, Xiaodong Peng iD, Sitong Li iD, Jue Wang iD, Jingrui Zhang iD, Yiwei Lai iD, Shijun Xia iD, Jingye Li iD, Zhen Wang iD, Gaifeng Hu, Qifan Li, Le Zhou und 15 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047527 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Lan Ren und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases Beijin…. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Catheter Ablation, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the growing use of catheter ablation for atrial fibrillation, large‐scale studies assessing the efficacy and safety of oral anticoagulation (OAC) after ablation, particularly in patients with high stroke risk, remain limited.

Methods

This prospective study enrolled consecutive patients from the China‐AF (China Atrial Fibrillation) registry between August 2011 and June 2022. Stroke risk was stratified by CHA 2 DS 2 ‐VA score as low (0–1), intermediate (2), or high (≥3). The study end points were thromboembolism (ischemic stroke or systemic embolism), and bleeding (International Society on Thrombosis and Hemostasis major bleeding and clinically relevant non‐major bleeding). A 6‐month landmark analysis was applied to evaluate the association of OAC with end points using incidence rates and Cox models.

Results

Among 13 669 patients (median follow‐up, 4.0 years), 2637 continued and 11 032 discontinued OAC at the 6‐month landmark. OAC was not associated with reduced thromboembolism risk across low‐ (adjusted hazard ratio [aHR], 1.11 [95% CI, 0.70–1.77]; P =0.649), intermediate‐ (aHR, 0.64 [95% CI, 0.36–1.16]; P =0.141) or high‐stroke risk patients (aHR, 1.05 [95% CI, 0.74–1.48]; P =0.801). In contrast, continued OAC was associated with higher bleeding risk, including clinically relevant non‐major bleeding across stroke risk strata, and International Society on Thrombosis and Hemostasis major bleeding among high‐risk patients (aHR, 2.32 [95% CI, 1.19–4.50]; P =0.013). These results were consistent across subgroups and sensitivity analyses.

Conclusions

In this large, real‐world cohort of patients with atrial fibrillation undergoing catheter ablation, continued OAC was not associated with lower thromboembolic risk, but with higher major bleeding risk among patients with CHA 2 DS 2 ‐VA scores ≥3. These findings support individualized post‐ablation anticoagulation strategies and warrant future investigation. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT06987825.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationCatheter AblationHemorrhageRegistriesThromboembolismAgedFemaleHumansMaleMiddle AgedAdministration, OralChinaIncidenceProspective StudiesRisk AssessmentRisk FactorsStrokeTreatment Outcome

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationoral anticoagulation

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Cardiology Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases Beijing China.

ORCID-Profile: Xiaodong Peng, Sitong Li, Jue Wang, Jingrui Zhang, Yiwei Lai, Shijun Xia, Jingye Li, Zhen Wang, Zixu Zhao, Zejun Yang, Mingxiao Li, Song Zuo, Songnan Li, Ribo Tang, Deyong Long, Xin Du, Jianzheng Dong, Caihua Sang, Changsheng Ma

Zitieren

APA

Ren, L., Peng, X., Li, S., Wang, J., Zhang, J., Lai, Y., Xia, S., Li, J., Wang, Z., Hu, G., Li, Q., Zhou, L., Zhao, Z., Yang, Z., Li, M., Liu, X., Guo, X., Zuo, S., Li, S., …, & Ma, C. (2026). Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047527

Vancouver

Ren L, Peng X, Li S, Wang J, Zhang J, Lai Y, et al. Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047527

BibTeX
@article{Ren2026,
  author = {Ren, Lan and Peng, Xiaodong and Li, Sitong and Wang, Jue and Zhang, Jingrui and Lai, Yiwei and Xia, Shijun and Li, Jingye and Wang, Zhen and Hu, Gaifeng and Li, Qifan and Zhou, Le and Zhao, Zixu and Yang, Zejun and Li, Mingxiao and Liu, Xiaoxia and Guo, Xueyuan and Zuo, Song and Li, Songnan and Zhou, Ning and Tang, Ribo and Long, Deyong and He, Liu and Du, Xin and Dong, Jianzheng and Sang, Caihua and Ma, Changsheng},
  title = {Thromboembolism and Bleeding Risks in Atrial Fibrillation: Outcomes of Oral Anticoagulation After Catheter Ablation},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047527}
}
Kostenlos starten →